Chinese Pharma Simcere Files IND For Humanized Rabbit Monoclonal Antibody
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Chinese drug manufacturer and distributor Simcere Pharmaceutical Group filed an investigational new drug application earlier this month with China's State FDA to launch a Phase I trial of APX003, a novel humanized rabbit monoclonal antibody to treat solid-tumor cancer
You may also be interested in...
Deals Of The Week: Mersana/Endo, Nuron/Akshaya, Array BioPharma/Foundation Medicine
The Domain Associates/Rusnano tie-up looks new on the surface, but is driven by a familiar imperative – the need to find new funding streams for biotechs still working to build up their exit value.
With Government Support, China Medical City Looks To Separate Itself From The Pack
NEW YORK - Perhaps the largest hurdle China Medical City faces with a U.S. audience is explaining how it differs from China's more established science and technology parks like Zhangjiang Hi Tech Park in Shanghai, Zhong-guan-cun Life Science Park in Beijing and BioBay in Suzhou
With Government Support, China Medical City Looks To Separate Itself From The Pack
NEW YORK - Perhaps the largest hurdle China Medical City faces with a U.S. audience is explaining how it differs from China's more established science and technology parks like Zhangjiang Hi Tech Park in Shanghai, Zhong-guan-cun Life Science Park in Beijing and BioBay in Suzhou